SRR8613763
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.450
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.310
- TNFA_SIGNALING_VIA_NFKB+0.270
- IL2_STAT5_SIGNALING+0.260
- PI3K_AKT_MTOR_SIGNALING+0.260
- APICAL_SURFACE+0.210
- COMPLEMENT+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ANGIOGENESIS-0.360
- OXIDATIVE_PHOSPHORYLATION-0.340
- MYC_TARGETS_V2-0.310
- E2F_TARGETS-0.290
- MYC_TARGETS_V1-0.280
- GLYCOLYSIS-0.260
- HYPOXIA-0.250
- PROTEIN_SECRETION-0.250
- UV_RESPONSE_DN-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5566453e-df41-4aab-8dd0-825efbece954 | — | — | 0.856 |
| 2 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.851 |
| 3 | SRR8613774 | — | D | 0.835 |
| 4 | ERR2208965 | — | — | 0.827 |
| 5 | 90242448-2567-4d5b-b015-43c0ce31f0ad | — | — | 0.826 |
| 6 | MBCProject_1037_T1_RNA | — | D | 0.826 |
| 7 | MNG443 | — | — | 0.819 |
| 8 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.817 |
| 9 | X1c87996e.59e7.495f.8c4e.f578c7e10ba8 | — | cohortMD2 | 0.805 |
| 10 | ERR2208913 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |